Publications
The case for adopting a broader perspective on value in Health Technology Assessment
3 March 2026
In this Whitepaper, we describe different perspectives that can be adopted in…
Novel devices: optimising drug delivery in multiple myeloma
9 December 2025
Biologics: Driving innovation in the treatment of multiple myeloma Biological…
A global landscape analysis of access to tumour-agnostic therapies
1 December 2025
Tumour-agnostic (TA) therapies represent a paradigm shift in oncology by…
Capturing the lived experiences of informal care in acute leukemia
20 November 2025
Providing informal care to someone living with acute leukemia imposes a severe…
Insights
Europe’s pharmaceutical policy choices – And what the United States stands to learn
18 March 2026
A recent policy discussion on Capitol Hill hosted by We Work For Health examined…
Around The World in HTAs: France – Three Core HTA Values
12 March 2026
In the latest edition of our Insights series, Around the World in HTAs, we…
Why do we expect obesity medicines to work differently?
5 March 2026
Weight regain after stopping GLP-1 medicines isn’t a treatment failure — it…
Global rare‑disease policy shifts: what are the implications for equitable access to orphan medicines?
1 March 2026
Rare diseases may affect only a small number of people, but together they impact…
Robust analysis, real-world problems
OHE research supports pragmatic solutions and stronger policy decisions
Areas of expertise
OHE’s expertise covers a wide range of topics
Health Technology Assessment (HTA)
Around The World in HTAs: France – Three Core HTA Values
In the latest edition of our Insights series, Around the World in HTAs, we explore the HTA system in France. A special…
The case for adopting a broader perspective on value in Health Technology Assessment
In this Whitepaper, we describe different perspectives that can be adopted in Health Technology Assessment (HTA), and some…
Drug Development/R&D
Europe’s pharmaceutical policy choices – And what the United States stands to learn
A recent policy discussion on Capitol Hill hosted by We Work For Health examined the lessons the United States might draw…
Global rare‑disease policy shifts: what are the implications for equitable access to orphan medicines?
Rare diseases may affect only a small number of people, but together they impact an estimated 300–400 million people…
Digital Health
The true cost and burden of frontotemporal dementia: Early insights into a pressing challenge
In recognition of Frontotemporal Dementia Awareness Week, OHE shares ongoing work quantifying the disease burden and…
OHE’s submission for the DHSC’s next 10 years of planning
This Insight summarises the recommendations OHE submitted towards the Department of Health & Social Care’s consultation…
Prevention
Turning around the NHS: Reflections on the 2025 OHE Annual Lecture
In this year's Annual Lecture, Prof Anita Charlesworth takes a closer look at the NHS 10 Year Health Plan, concluding that…
New OHE model estimates COVID-19 could be associated with costs of £7 billion a year in the UK, without annual autumn vaccinations
A newly released report commissioned by Moderna modelled a one-year scenario without annual COVID-19 autumn vaccinations.